RBC Capital analyst Brian Abrahams notes that regular abstracts for the WMS 2024 Congress were released today and calls the abstracts released by Sarepta for Elevidys “directionally positive.” The firm, which thinks the data should help facilitate broad uptake and reduce Street concerns about utilization, has an Outperform rating and $182 price target on Sarepta shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT: